Fortress Biotech, Inc. (FBIO) Stock

Fortress Biotech, Inc. is a dynamic biopharmaceutical company focused on the development and commercialization of a diverse portfolio of pharmaceutical and biotechnology products. The company markets a range of dermatology treatments, including Ximino and Targadox for acne vulgaris, Exelderm for fungal infections, Qbrexza for hyperhidrosis, Luxamend for wound management, and Accutane for severe acne. In addition to its marketed products, Fortress Biotech advances a robust pipeline of late-stage candidates, such as intravenous Tramadol for post-operative pain, CUTX-101 for Menkes disease, and innovative therapies like MB-107 and MB-207 for severe combined immunodeficiency.

Fortress Biotech is also at the forefront of developing promising early-stage product candidates targeting various challenging diseases. These include Cosibelimab for metastatic cancers, CK-101 for EGFR mutation-positive NSCLC, CAEL-101 for amyloidosis, and CEVA101 for traumatic brain injury. The company's preclinical initiatives encompass gene therapies like AAV-ATP7A and AVTS-001, as well as innovative platforms targeting oncology and neurological disorders.

Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress Biotech collaborates extensively with leading universities, research institutes, and pharmaceutical companies to accelerate the advancement of its diverse pipeline. Formerly known as Coronado Biosciences, the company rebranded as Fortress Biotech in 2015, reflecting its strategic focus on fortifying the healthcare landscape through innovative therapies and collaborative partnerships.